Efficacy and safety of oral phenylephrine: Systematic review and meta-analysis

Annals of Pharmacotherapy

Volumn 41, Issue 3, 2007, Pages 381-390

  Hatton, Randy C ^a,b   Winterstein, Almut G ^b   McKelvey, Russell P ^c   Shuster, Jonathan ^d   Hendeles, Leslie ^d  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c SARASOTA MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Nasal airway resistance; Nasal decongestants; Phenylephrine

Indexed keywords

DECONGESTIVE AGENT; PHENYLEPHRINE; PLACEBO;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART RATE; HUMAN; META ANALYSIS; NOSE AIRWAY RESISTANCE; NOSE CONGESTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

AIRWAY RESISTANCE; HUMANS; NASAL DECONGESTANTS; NASAL OBSTRUCTION; PHENYLEPHRINE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 34047210056     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H679     Document Type: Review

References (36)

1. Department of Health, Education, and Welfare. Food and Drug Administration. Establishment of a monograph for OTC cold, cough, allergy, bronchodilator, and antiasthmatic products. Fed Regist 1976;41:38399-400. www.fda.gov/OHRMS/Dockets/98fr/76-22710.PDF (accessed 2005 Dec 8).
2. Hengstmann JH, Goronzy J. Pharmacokinetics of 3H-phenylephrine in man. Eur J Clin Pharmacol 1982;21:335-41. DOI 10.1007/BF00637623
3. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343:1826-32. DOI 10.1056/ NEJM200012213432501
4. Department of Health and Human Services. Food and Drug Administration. Phenylpropanolamine-containing drug products for over-the-counter human use; tentative final monographs. Fed Regist 2005;70:75988-98. www.fda.gov/OHRMS/ DOCKETS/98fr/E5-7646.htm (accessed 2006 Jun 25).
5. Combat Methamphetamine Epidemic Act of 2005 (H.R. 3889, Title VII). http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname= 109_cong_ bills&docid=f:h3199enr.txt.pdf (accessed 2006 Sept 4).
6. Murty S, Sansgiry SS. Pseudoephedrine laws in the US-are we doing enough (letter)? Ann Pharmacother 2006;40:1213-5. Epub 30 May 2006. DOI 10.1345/aph.1H032
7. Department of Health and Human Services. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; tentative final monograph for over-the-counter nasal decongestant drug products. Fed Regist 1985;50:2226. www.fda.gov/cder/ otcmonographs/Cold&Cough/nasal_decongestant_ TFM_19850115.pdf (accessed 2006 Sept 4).
8. Hendeles L. Selecting a decongestant. Pharmacotherapy 1993;13(6 pt 2):129S-34S.
9. Hendeles L, Hatton RC. Oral phenylephrine: an effective replacement for pseudoephedrine (letter)? J Allergy Clin Immunol 2006;118:279-80. DOI 10.1016/j.jaci.2006.03.002
10. OTC cold, cough, allergy, bronchodilator and antiasthmatic drug products. In: Compilation of OTC drug regulations: a compilation of selected Federal Register documents of significance to OTC drugs published in the Federal Register since 1960, part I, vol. 3. Washington, DC: The Proprietary Association, 1976 with periodic updates.
11. Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy 1993;13(6 pt 2):116S-28S, 143S-6S.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. DOI 10.1016/0197-2456(86)90046-2
13. Cohen BM. Objective and subjective evaluation of phenylephrine HCl (5 mg) versus placebo tablets. In: FDA OTC volume 04088B. June 1975.
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. DOI 10.1002/sim.1186
15. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in a meta-analysis. In: Egger M, Davey Smith G, Altman DG, eds, Systematic reviews in health care: meta-analysis in context. London: BMJ Publications, 2001:285-312.
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
17. Memo to Lands from FP Luduena. Comparative study of the effects of Neo-Synephrine HCL and Propadrine HCL on nasal air resistance (NAR), blood pressure and pulse rate of volunteers. In: FDA OTC volume 040298. April 23, 1959.
18. McLaurin JW, Shipman WF, Rosedale R. Oral decongestants. A double-blind comparison study of the effectiveness of four sympathomimetic drugs: objective and subjective. Laryngoscope 1961;71:54-67.
19. Memo to Suter from NA Hulme. Nasal decongestant study by Elizabeth Biochemical No 1. In: FDA OTC volume 040298. June 1967.
20. Memo to Wessinger from NA Hulme. Nasal decongestant study by Elizabeth Biochemical No 2. In: FDA OTC volume 040298. January 1968.
21. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Elizabeth Biochemical Study No 3. In: FDA OTC volume 040298. June 1969.
22. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Cintest Labs Study No 1. In: FDA OTC volume 040298. April 1969.
23. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Huntingdon Research Center Study No 1. In: FDA OTC volume 040298. May 1969.
24. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Huntingdon Research Center Study No 2. In: FDA OTC volume 040298. June 1969.
25. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Elizabeth Biochemical Study No 4. In: FDA OTC volume 040298. August 1969.
26. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Cintest Study No 2. In: FDA OTC volume 040298. January 1970.
27. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Cintest Study No 3. In: FDA OTC volume 040298. May 1970.
28. Memo to Blackmore from NA Hulme. Neo-Synephrine-Elizabeth Biochemical Laboratory Study No 5. In: FDA OTC volume 040298. May 1970.
29. Bickerman HA. In: The Proprietary Association. Current research methodology in the evaluation of proprietary medicines: proceedings of a conference sponsored by the Scientific Development Committee of the Proprietary Association. Physiologic and pharmacologic studies on nasal airway resistance (RN). December 8, 1971.
30. Cohen BM. Clinical and physiologic quot;significance" of drug-induced changes in nasal flow/resistance. Eur J Clin Pharmacol 1972;5:81-6. DOI 10.1007/BF00561750
31. Sternstein HJ, Schur MO. Quantitative study of nasal obstruction: a new method. Arch Otolaryngol 1936;23:475-9.
32. McLaurin JW, Shipman WF, Kirkley DE. A modified technique of rhinometry: with a preliminary note on the effect of nasal decongestants administered orally. Laryngoscope 1960;70:155-65.
33. Blanchard CL, Borsanyi SJ, Grubb TC. Evaluation of nasal decongestant drugs. Eye Ear Nose Throat Mon 1964;43(10):76-82.
34. Cohen GM, McIlreath FJ. Airway resistance measurements in the internist's office: routine determination in the diagnosis and care of breathless patients. J Asthma Res 1968;6:23-35.
35. Chua SS, Benrimoj SI. Non-prescription sympathomimetic agents and hypertension. Med Toxicol 1988;3:387-417.
36. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994;309:1351-5.